William Blair downgraded STAAR Surgical from Outperform to Mkt Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/15/2024 | $50.00 → $37.00 | Equal-Weight → Underweight | Morgan Stanley |
| 6/11/2024 | $46.00 | Neutral → Buy | BTIG Research |
| 3/11/2024 | $30.00 → $50.00 | Hold → Buy | Stifel |
| 12/5/2023 | Buy → Hold | Needham | |
| 12/4/2023 | $35.00 | Equal-Weight | Morgan Stanley |
| 9/15/2023 | Buy → Hold | The Benchmark Company | |
| 8/3/2023 | $77.00 → $48.00 | Buy → Hold | Canaccord Genuity |
| 6/7/2023 | Outperform → Mkt Perform | William Blair |
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
Morgan Stanley downgraded STAAR Surgical from Equal-Weight to Underweight and set a new price target of $37.00 from $50.00 previously
BTIG Research upgraded STAAR Surgical from Neutral to Buy and set a new price target of $46.00
Stifel upgraded STAAR Surgical from Hold to Buy and set a new price target of $50.00 from $30.00 previously
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with STAAR Management at the upcoming Stephens Annual Investment Conference, which will be held in Nashville, TN. Event: Stephens Annual Investment Conference (NASH2024) Management Attendee: Patrick F. Williams, Chief Financial Officer Date: Wednesday, November 20, 2024 Time: 11:00 a.m. ET / 8:00 a.m. PT Location: Live Webcast The live webcast link includes an option to pre-register. An online replay of the webcast will also be
Net Sales Up 10% to $88.6 Million Driven by Growth in All Regions Americas Up 14%, EMEA Up 12% and APAC Up 9% Market Building Initiatives Drive EVO ICL™ Uptake and Reinforce Opportunity STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended September 27, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030604379/en/ Third Quarter 2024 Overview Net sales of $88.6 million, up 10% from prior year quarter ICL sales of $89.1 million
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the third quarter ended September 27, 2024, on Wednesday, October 30, 2024, after the market close. Event: STAAR Surgical 3Q 2024 Financial Results Webcast Date: Wednesday, October 30, 2024 Time: 4:30 p.m. ET / 1:30 p.m. PT Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=fmU0YbKB STAAR will also host an earnings webcast on Wednesday, October 30 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and op
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the third quarter ended September 27, 2024, on Wednesday, October 30, 2024, after the market close. Event: STAAR Surgical 3Q 2024 Financial Results Webcast Date: Wednesday, October 30, 2024 Time: 4:30 p.m. ET / 1:30 p.m. PT Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=fmU0YbKB STAAR will also host an earnings webcast on Wednesday, October 30 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and op
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the second quarter ended June 28, 2024, on Wednesday, August 7, 2024, after the market close. Event: STAAR Surgical 2Q 2024 Financial Results Webcast Date: Wednesday, August 7, 2024 Time: 4:15 p.m. ET / 1:15 p.m. PT Location: https://staar-surgical-2q24-earnings.open-exchange.net/ STAAR will also host an earnings webcast on Wednesday, August 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress. The
EVO ICL™ Continues to Outpace Refractive Industry Growth Record Quarterly U.S. Sales and Multiple Strategic Agreements Secured Reiterates Fiscal 2024 Net Sales Outlook and Increases Adjusted EBITDA STAAR Surgical Company (NASDAQ:K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024. First Quarter 2024 Overview Net sales up 5% to $77.4 million and up 7% in constant currency ICL sales up 9% and units up 2% Gross margin at 78.9% vs. 78.3% year ago Net loss of $3.3 million or $0.07 loss per share vs. net
8-K/A - STAAR SURGICAL CO (0000718937) (Filer)
10-Q - STAAR SURGICAL CO (0000718937) (Filer)
8-K - STAAR SURGICAL CO (0000718937) (Filer)
BTIG analyst Ryan Zimmerman maintains Staar Surgical (NASDAQ:STAA) with a Buy and raises the price target from $46 to $53.
Staar Surgical (NASDAQ:STAA) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 2 1 0 Last 30D 0 0 0 1 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 0 2 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $44.2, a high estimate of $55.00, and a low estimate of $37.00. Experiencing a 2.86% decline, the current average
New Appointments Underscore Commitment to Driving Innovation and Industry-Leading Growth STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company's executive committee and report to Tom Frinzi, STAAR Surgical's President and CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501408389/en/Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo:
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, to its Board of Directors, effective March 12, 2024. "Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry," said Aimee Weisner, Chair
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023. "We welcome Lilian Zhou as a new member to our Board of Directors. Lilian is an accomplished investment portfolio manager who worked at highly regarded Wall Street investment institutions before founding her own firm a decade ago," said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical's Board of Directors. "We look forward to Lilian's contributions as a former institutional shar
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)